FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
NCT06669117
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
140
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumor
MET Alteration
Interventions
DRUG:
VERT-002
Sponsor
Pierre Fabre Medicament